Navinci and BrainZell entered a collaboration to apply Navinci’s in situ PLA technology to spatial proteomics experiments in brain organoids. The companies said they will use the platform to evaluate how spatial assays can map brain biology and drug response in three-dimensional models. The work targets an ongoing gap in translational neuroscience: organoids can represent developmental complexity, but assays that retain location-specific protein information are often difficult to scale or standardize. In situ PLA is positioned as a way to keep spatial context while measuring protein interactions. If successful, the partnership could support compound screening and mechanism work for neurologic programs, including target validation tied to region-specific biology inside organoids.